Wang FM, Mo P, Yan X, Lin XY, Fu ZC. Present situation and prospect of immunotherapy for unresectable locally advanced esophageal cancer during peri-radiotherapy. World J Gastrointest Oncol 2024; 16(1): 1-7 [PMID: 38292836 DOI: 10.4251/wjgo.v16.i1.1]
Corresponding Author of This Article
Zhi-Chao Fu, MD, PhD, Doctor, Department of Radiotherapy, Fuzong Clinical Medical College (900th Hospital), Fujian Medical University, No. 156 West Second Ring Road North, Fuzhou 350025, Fujian Province, China. fauster1112@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Jan 15, 2024; 16(1): 1-7 Published online Jan 15, 2024. doi: 10.4251/wjgo.v16.i1.1
Present situation and prospect of immunotherapy for unresectable locally advanced esophageal cancer during peri-radiotherapy
Feng-Mei Wang, Peng Mo, Xue Yan, Xin-Yue Lin, Zhi-Chao Fu
Feng-Mei Wang, Department of Obstetrics and Gynecology, Fuzong Clinical Medical College (900th Hospital), Fujian Medical University, Fuzhou 350025, Fujian Province, China
Feng-Mei Wang, Department of Obstetrics and Gynecology, Dongfang Hospital, Xiamen University, Fuzhou 350025, Fujian Province, China
Peng Mo, Xue Yan, Xin-Yue Lin, Zhi-Chao Fu, Department of Radiotherapy, Fuzong Clinical Medical College (900th Hospital), Fujian Medical University, Fuzhou 350025, Fujian Province, China
Zhi-Chao Fu, Department of Radiotherapy, Dongfang Hospital, Xiamen University, Fuzhou 350025, Fujian Province, China
Author contributions: Wang FM, Mo P, Yan X contributed equally to this work; Fu ZC designed the research study; Wang FM, Mo P, Yan X, Lin XY, Fu ZC performed the research; Wang FM, Mo P, Yan X, Lin XY analyzed the data and wrote the manuscript; all authors have read and approve the final manuscript.
Supported byNatural Science Foundation of Fujian Province, No. 2021J011259.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi-Chao Fu, MD, PhD, Doctor, Department of Radiotherapy, Fuzong Clinical Medical College (900th Hospital), Fujian Medical University, No. 156 West Second Ring Road North, Fuzhou 350025, Fujian Province, China. fauster1112@126.com
Received: October 21, 2023 Peer-review started: October 21, 2023 First decision: November 7, 2023 Revised: November 14, 2023 Accepted: December 6, 2023 Article in press: December 6, 2023 Published online: January 15, 2024 Processing time: 82 Days and 4.7 Hours
Abstract
Four major studies (Checkmate577, Keynote-590, Checkmate649 and Attraction-4) of locally advanced esophageal cancer published in 2020 have established the importance of immunotherapy, represented by anti-programmed death protein (PD)-1 in postoperative adjuvant treatment and advanced first-line treatment of locally advanced or advanced esophageal cancer and esophagogastric junction cancer, from the aspects of proof of concept, long-term survival, overall survival rate and progression-free survival. For unresectable or inoperable nonmetastatic esophageal cancer, concurrent radiotherapy and chemotherapy is the standard treatment recommended by various guidelines. Because its curative effect is still not ideal, it is necessary to explore radical radiotherapy and chemotherapy in the future, and it is considered to be promising to combine them with immunotherapeutic drugs such as anti-PD-1. This paper mainly discusses how to combine radical concurrent radiotherapy and chemotherapy with immunotherapy for unresectable local advanced esophageal cancer.
Core Tip: For unresectable or inoperable non-metastatic esophageal cancer, concurrent radiotherapy and chemotherapy is the standard treatment recommended by various guidelines. Because its curative effect is still not ideal, it is still necessary to explore radical radiotherapy and chemotherapy in the future, and it is considered to be very promising to combine with immune drugs represented by anti-programmed death protein-1. This paper mainly discusses how to combine radical concurrent radiotherapy and chemotherapy with immunotherapy for unresectable local late esophageal cancer.
